ABSTRACT
Objective Poly(ADP-ribose) polymerase (PARP) inhibitors are used for targeted therapy for ovarian cancer with homologous recombination deficiency (HRD). In this study, we aimed to develop a homologous recombination deficiency prediction model to predict the genomic integrity (GI) index of the SOPHiA DDM HRD Solution from the Oncomine Comprehensive Assay (OCA) Plus. We also tried to a find cut-off value of the genomic instability metric (GIM) of the OCA Plus that correlates with the GI index of the SOPHiA DDM HRD Solution.
Methods We included 87 cases with high-grade ovarian serous carcinoma from five tertiary referral hospitals in Republic of Korea. We developed an HRD prediction model to predict the GI index of the SOPHiA DDM HRD Solution. As predictor variables in the model, we used the HRD score, which included percent loss of heterozygosity (%LOH), percent telomeric allelic imbalance (%TAI), percent large-scale state transitions (%LST), and the genomic instability metric (GIM), provided by the OCA Plus. To build the model, we employed a penalized logistic regression technique.
Results The final model equation is −21.77 + 0.200 × GIM + 0.102 × %LOH + 0.037 × %TAI + 0.261 × %LST. To improve the performance of the prediction model, we added a borderline result category to the GI results. Cases with predicted values between −3 and 3 were classified as borderline. The accuracy of our HRD status prediction model was 0.947 for the training set and 0.958 for the test set. The accuracy of HRD status using GIM with a cut-off value of 16 was 0.911.
Conclusions The Oncomine Comprehensive Assay Plus provides a reliable biomarker for homologous recombination deficiency.
What is already known on this topic
The Oncomine Comprehensive Assay Plus is a targeted next-generation sequencing assay designed to detect genetic alterations in solid tumors. It has not been validated as a biomarker for PARP inhibitor response through clinical trials or a concordance test with a Food and Drug Administration–approved homologous recombination deficiency test.
What this study adds
This study introduces a predictive model for homologous recombination deficiency using data from the Oncomine Comprehensive Assay Plus, which correlates with the SOPHiA DDM HRD Solution. The study provides evidence that the Oncomine Comprehensive Assay Plus is a reliable biomarker for homologous recombination deficiency.
How this study might affect research, practice or policy
The strong agreement between the Oncomine Comprehensive Assay Plus and the SOPHiA DDM HRD Solution suppports its potential as a biomarker for predicting PARP inhibitor response. This finding could have implications for PARP inhibitor-related research, clinical practice, and regarding their use in clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Catholic University of Seoul Saint Mary' Hospital gave ethical approval for this work (KC18TNSI0361) Ethics committee/IRB of CHA Bundang Medical Center, CHA University gave ethical approval for this work (2023-01-010-001)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
